Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a vaginal probiotic stick around? new study follows women who got the treatment

NCT ID NCT07305844

Disease control Sponsor: Caroline Mitchell Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 20, 2026 · Updated 3 times

Summary

This study is for women who previously received a vaginal probiotic (LC106) for bacterial vaginosis in an earlier trial. Researchers want to see if the good bacteria from the probiotic can stay in the vagina over time. About 71 women will be followed, and the main goal is to check if the probiotic bacteria are still present at meaningful levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LC106 (a vaginal tablet containing 6 strains of Lactobacillus crispatus)
What this could lead to
If successful, this could show that the probiotic consistently colonizes the vagina, pointing toward a way to restore healthy bacteria and reduce recurrent bacterial vaginosis.
What could go wrong
This is a very early (Phase 1), small, open-label study with no placebo group, so results may not prove effectiveness. The probiotic may not colonize as expected or could cause irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

26 people

The number who actually took part.

Started

Apr 2026

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Previous participant in the VIBRANT study, randomized to active LBP * Nugent score 4-10 Exclusion Criteria: * Infection requiring antibiotics detected on screening labs * Use of oral or vaginal antibiotics in the 30 days prior to screening * Use of an oral or vaginal probiotic in the 30 days prior to screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bacterial vaginosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial vaginosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bacterial vaginosis

Contacts and locations

Locations

  • CAPRISA

    Vulindlela, South Africa

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.